CLINICAL_TRIALS
trial_result
· 2015-04-10
Clinical Trial Update: High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia [Phase 2]
Summary
This Phase 2 study evaluated high-dose ranibizumab (2.0 mg) for nonproliferative idiopathic parafoveal telangiectasia; the trial has completed and results were …
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eye Center of Northern Colorado, P.C. | Conditions: Retinal Diseases, Telangiectasis | Phase 2 | Status: COMPLETED | Results posted: 2015-04-10